Sia Daneshmand, MD, Keck Medicine of USC, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, highlight two trials in progress in NMIBC, including nadofaragene firadenovec early use and outcomes in a US real-world setting as well as cretostimogene grenadenorepvec for IR-NMIBC following TURBT.
ABLE-41 and PIVOT-006 for NMIBC: Trials With Promise
By Sia Daneshmand, MD, Christopher Wallis, MD, PhD, FRCSC - Last Updated: February 6, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.